adding glp-1 to insulin A new ACP Journal Club is online now. Read about tailored precision immunotherapy for #sepsis, RAs for adults with #T1D and overweight or obesity, and more new evidence for #InternalMedicine from Who Should Explore GLP-1 Shots

Hence, weve extended our mission to deliver not just the benefits but also your safety in consuming our products

Timeline of Regulatory Milestones 2005: Exenatide (Byetta): First GLP-1 agonist approved, twice-daily injections 2010: Liraglutide (Victoza): Longer-lasting, once-daily injection 2014: Dulaglutide (Trulicity): Once-weekly injection arrives 2017: Semaglutide (Ozempic): First once-weekly injection for diabetes with powerful weight-loss effects 2019: Oral semaglutide (Rybelsus): First GLP-1 pill makes it past the stomachs defenses 2021: High-dose semaglutide (Wegovy): FDA approval for obesity treatment 2022: Tirzepatide (Mounjaro): First dual GLP-1/GIP agonist for diabetes 2023: Tirzepatide (Zepbound): Expanded approval for obesity 20232024 : Widespread shortages: Skyrocketing demand for GLP-1s leads to limited availability The shortage that began in late-2023, driven by soaring off-label demand and supply-chain bottlenecks left millions of patients unable to fill even maintenance scripts

This new group of medications are some of the best we have seen, and very promising, and a lot of people are having great results

Physical activity level

Apc fl/fl

W., Ostermann, R